Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sven Mahner

Showing results (331-340 of 455) with videos related to

Pageof 46
Sort By:
Biomedicines|July 2, 2021
Platelet-Activating Factor Acetylhydrolase Expression in BRCA1 Mutant Ovarian Cancer as a Protective Factor and Potential Negative Regulator of the Wnt Signaling PathwayYue Liao, Susann Badmann, Till Kaltofen, et al.
Journal of Reproductive Immunology|March 16, 2024
Placental expression of inflammatory Galectin-12 is associated with gestational diabetesChristina Buschmann, Laura Unverdorben, Julia Knabl, et al.
Cancer Science|April 14, 2012
Validating the impact of a molecular subtype in ovarian cancer on outcomes: a study of the OVCAD ConsortiumDietmar Pils, Gudrun Hager, Dan Tong, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 6, 2025
Impact of lymphadenectomy rates in the quality assurance program in early ovarian cancer of the AGO Study Group - Real-world observationsPauline Wimberger, Jacobus Pfisterer, Andreas du Bois, et al.
Journal of Cancer Research and Clinical Oncology|May 2, 2023
Nuclear receptor co-repressor NCOR2 and its relation to GPER with prognostic impact in ovarian cancerJuliane Reichenbach, Patricia Fraungruber, Doris Mayr, et al.
Frontiers in Oncology|October 11, 2021
Actin Beta-Like 2 as a New Mediator of Proliferation and Migration in Epithelial Ovarian CancerNicole Elisabeth Topalov, Doris Mayr, Clemens Scherer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 18, 2019
TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7)Alexander Reuss, Andreas du Bois, Philipp Harter, et al.
Archives of Gynecology and Obstetrics|October 16, 2014
Surgical and systemic management of endometrial cancer: an international surveyChristina Fotopoulou, Robert Kraetschell, Sean Dowdy, et al.
Carcinogenesis|October 6, 2019
miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional studyKonstantina Panoutsopoulou, Margaritis Avgeris, Konstantinos Mavridis, et al.
Cancers|April 30, 2021
A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian CancerLiina Salminen, Elena Ioana Braicu, Mitja Lääperi, et al.
Pageof 46

Showing results (331-340 of 455) with videos related to

Sort By:
Pageof 46
Biomedicines|July 2, 2021
Platelet-Activating Factor Acetylhydrolase Expression in BRCA1 Mutant Ovarian Cancer as a Protective Factor and Potential Negative Regulator of the Wnt Signaling PathwayYue Liao, Susann Badmann, Till Kaltofen, et al.
Journal of Reproductive Immunology|March 16, 2024
Placental expression of inflammatory Galectin-12 is associated with gestational diabetesChristina Buschmann, Laura Unverdorben, Julia Knabl, et al.
Cancer Science|April 14, 2012
Validating the impact of a molecular subtype in ovarian cancer on outcomes: a study of the OVCAD ConsortiumDietmar Pils, Gudrun Hager, Dan Tong, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 6, 2025
Impact of lymphadenectomy rates in the quality assurance program in early ovarian cancer of the AGO Study Group - Real-world observationsPauline Wimberger, Jacobus Pfisterer, Andreas du Bois, et al.
Journal of Cancer Research and Clinical Oncology|May 2, 2023
Nuclear receptor co-repressor NCOR2 and its relation to GPER with prognostic impact in ovarian cancerJuliane Reichenbach, Patricia Fraungruber, Doris Mayr, et al.
Frontiers in Oncology|October 11, 2021
Actin Beta-Like 2 as a New Mediator of Proliferation and Migration in Epithelial Ovarian CancerNicole Elisabeth Topalov, Doris Mayr, Clemens Scherer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 18, 2019
TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7)Alexander Reuss, Andreas du Bois, Philipp Harter, et al.
Archives of Gynecology and Obstetrics|October 16, 2014
Surgical and systemic management of endometrial cancer: an international surveyChristina Fotopoulou, Robert Kraetschell, Sean Dowdy, et al.
Carcinogenesis|October 6, 2019
miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional studyKonstantina Panoutsopoulou, Margaritis Avgeris, Konstantinos Mavridis, et al.
Cancers|April 30, 2021
A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian CancerLiina Salminen, Elena Ioana Braicu, Mitja Lääperi, et al.
Pageof 46